UBS downgrades Coherus Oncology Inc (CHRS) rating to a Neutral

Coherus Oncology Inc’s recently made public that its Director Wahlstrom Mats unloaded Company’s shares for reported $73881.0 on May 23 ’25. In the deal valued at $0.74 per share,99,988 shares were sold. As a result of this transaction, Wahlstrom Mats now holds 0 shares worth roughly $0.0.

UBS downgraded its Coherus Oncology Inc [CHRS] rating to a Neutral from a a Buy in a research note published on August 16, 2024; the price target was decreased to $1.50 from $4. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. Maxim Group also remained covering CHRS and has decreased its forecast on November 08, 2023 with a “Hold” recommendation from previously “Buy” rating. Citigroup started covering the stock on July 24, 2023. It rated CHRS as “a Buy”.

Price Performance Review of CHRS

On Monday, Coherus Oncology Inc [NASDAQ:CHRS] saw its stock fall -1.12% to $0.87. Over the last five days, the stock has lost -18.88%. Coherus Oncology Inc shares have fallen nearly -43.64% since the year began. Nevertheless, the stocks have fallen -37.10% over the past one year.

How much short interest is there in Coherus Oncology Inc?

A steep rise in short interest was recorded in Coherus Oncology Inc stocks on 2025-07-15, dropping by -0.71 million shares to a total of 31.23 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 31.94 million shares. There was a decline of -2.29%, which implies that there is a negative sentiment for the stock.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.